Market Access
Week ending August 22, 2026
1. Access and affordability questions this week
Baseline week: 10 questions, 70 responses; no prior-week comparison is available.
Access-relevant themes were concentrated in product selection and substitution rather than explicit price or insurance questions:
- Brand/generic and product substitution — ~14 responses across two questions:
- “I’m comparing ivermectin brands like Stromectol vs Heartgard—are these the same drug or different uses?”
- “What are the main ways brand and generic products are described differently?”
Responses generally distinguished human versus veterinary products and described generic products as having the same active ingredient.
- Formulation/product selection — 7 responses:
“What’s the difference between ivermectin used orally in tablets and ivermectin used topically in creams—are brands marketed differently in practice?” - Off-label access risk — at least several question sets, with 17 off-label tags overall:
Off-label use arose particularly in the scabies question and the COVID-19 prescribing-information question. No direct questions asked about price, insurance coverage, copay, prior authorization, or formulary status.
2. How substitution questions are being handled
AI answers provide some useful product distinctions, but they largely stop at clinical or labeling information:
- The Stromectol/Heartgard responses repeatedly say the products contain ivermectin but are “different products” and “usually not interchangeable.” This is an important access safeguard, but answers do not consistently tell patients to confirm the product, route, patient population, and prescription with the pharmacist.
- Brand/generic responses focus on naming, inactive ingredients, formulation, and bioequivalence. They do not explain that a pharmacy may substitute a generic based on formulary rules, or suggest asking whether the generic is covered and what the patient’s out-of-pocket cost would be.
- The oral/topical responses explain that products are formulated for different routes and uses, but do not clearly distinguish a clinically similar active ingredient from a pharmacy-authorized substitution. One response mentions compounded products without providing a practical next step.
3. Off-label coverage risk visibility
Coverage implications are effectively absent. Responses describe scabies use as “off-label in some countries” and COVID-19 use as unsupported by prescribing information, but do not add that off-label status may result in noncoverage, higher patient cost, or a need for prior authorization or an exception request. This is a clear Market Access completeness gap.
4. Trend across weeks
No rising, falling, or steady trend can be established. The available history contains only this week, so substitution, off-label-coverage, and hedged/deflected access questions should be treated as baseline measures. The overall volume of hedging/disclaimer tags was high at 62, but access-specific deflection cannot be quantified from the available data.
5. Recommended actions
- Develop a patient-facing FAQ on brand/generic and formulary substitution, tied to the generic question and 10 biosimilar/generic tags; include what to ask the pharmacist about coverage, cost, and prescriber approval.
- Add a “not automatically interchangeable” product-identification prompt for human versus veterinary and oral versus topical products.
- Equip the support/hub team with off-label coverage language, prompted by 17 off-label tags: explain that reimbursement may vary and direct patients to their plan, pharmacist, or prescriber.
- Begin tracking explicit cost, insurance, formulary, and pharmacy-counter queries separately; no trend or action prioritization is possible without that baseline.